Otto Hemminki

Otto Hemminki is a Researcher at the University of Helsinki, associated with Clinicum. His work focuses on cancer genetics, oncolytic virotherapy, and environmental risk factors in hereditary cancers. He has contributed to collaborative research on familial cancer clustering, particularly in urological and solid tumors, and is involved in clinical trials using oncolytic adenoviruses combined with immunotherapy.

• Education: Docent in Cancer Biology (University of Helsinki, 2018).

Research Interests span familial cancer risks, germline mutations, and immunotherapy. His recent work explores the intersection of genetic predisposition and environmental causation in cancers like colorectal, prostate, and lung. He also investigates oncolytic viral delivery systems to enhance anti-tumor immunity.

Publications highlight his contributions to understanding age-specific cancer risks, checkpoint blockade in renal carcinoma, and recurrence patterns in non-muscle invasive bladder cancer. While his affiliations and projects align with HUS Cancer Center, specific grants or awards for Otto are not detailed in the provided texts.